心脏结节病预后与复发:BMIPP SPECT与FDG-PET系列评估
该回顾性研究分析了73例接受泼尼松治疗的心脏结节病患者,共250套BMIPP SPECT与FDG-PET影像。复发组初始BMIPP总缺损评分(BDS)显著高于无复发组(20±13 vs 14±12,P=0.041)。BDS≥16患者主要不良心脏事件(MACE)发生率显著更高(log-rank P=0.016),而SUVmax≥4与<4者MACE发生率相当。
要点
- BMIPP总缺损评分(BDS)是心脏结节病复发和MACE的预测标志物。
- BDS≥16患者MACE发生率显著高于BDS<16者(log-rank P=0.016)。
- SUVmax≥4与<4患者MACE发生率无显著差异。
核心结论
- BDS是心脏结节病复发和MACE的预测标志物,SUV与MACE无关。
- 以泼尼松治疗所致SUV变异性定义的复发见于约30%的心脏结节病患者。
研究设计与样本
- 回顾性分析73例心脏结节病患者,共250套BMIPP SPECT与FDG-PET影像,平均随访3.5年。
- 纳入标准为BMIPP与FDG-PET检查间隔在2个月内。
- 无复发组定义为心肌SUVmax连续≥2年<4。
主要发现
- 复发组(N=21)BDS显著高于无复发组(20±13 vs 14±12,P=0.041)。
- BDS≥16患者MACE发生率显著高于BDS<16患者(log-rank P=0.016)。
- SUVmax≥4与<4患者MACE发生率相当。
关键数值与推荐
- 复发组BDS为20±13,无复发组为14±12(P=0.041)。
- BDS≥16为MACE风险增高的临界值(log-rank P=0.016)。
- 心肌SUVmax<4持续≥2年定义为无复发。
临床怎么用
- 对心脏结节病患者可采用BMIPP SPECT评估心肌损伤程度,BDS≥16提示复发和MACE风险较高。
- FDG-PET的SUVmax不宜单独用于MACE风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We analyzed 18F-Fludeoxyglucose positron emission tomography (FDG-PET) and 123I-betamethyl-p-iodophenyl-pentadecanoic acid (BMIPP) single-photon emission computed tomography (SPECT) performed for cardiac sarcoidosis (CS) patients taking prednisolone, identified recurrence by FDG-PET, and investigated BMIPP as a recurrence and prognostic factor in CS. METHODS AND RESULTS: CS patients who underwent BMIPP and FDG-PET within 2 months were enrolled. The recurrence-free group included patients with standardized uptake value (SUVmax) < 4 in the myocardium consecutively for ≥ 2 years. The total BMIPP SPECT defect score (BDS) was used to estimate myocardial damage. The predictability of the initial BDS and SUVmax for major adverse cardiac events (MACE) was analyzed using Kaplan-Meier analysis. Overall, 73 patients and 250 BMIPP and FDG-PET sets were analyzed retrospectively (mean follow-up, 3.5 years). The BDS was significantly greater for the recurrence group (N = 21) vs recurrence-free group (20 ± 13 vs 14 ± 12, P = 0.041). Patients with BDS ≥16 had a significantly higher MACE rate than patients with BDS < 16 (log-rank test, P = 0.016). However, MACE occurrence was comparable between patients with SUVmax ≥ 4 and < 4. CONCLUSIONS: BDS is a predictive marker of recurrence and MACE. SUV is not related to MACE. Recurrence, defined by prednisolone treatment-induced SUV variability, was observed in approximately 30% of CS patients.
引用
- Yamamoto A, Nagao M, Watanabe E, et al. Prognosis and recurrence in cardiac sarcoidosis: Serial assessment of BMIPP SPECT and FDG-PET. J Nucl Cardiol. 2021. PMID: 33728571. doi:10.1007/s12350-021-02567-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。